Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||human placental insulin receptor.|
|Storage buffer||PBS, pH 7|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunoprecipitation (IP)||1-10 µg/ml|
|Western Blot (WB)||1-10 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunoprecipitation (IP)||See 1 publications below|
MA1-10865 detects Insulin Receptor from human samples. Low cross-reactivity with bovine and rabbit samples.
MA1-10865 has been successfully used in Western blot and immunoprecipitation applications.
The MA1-10865 immunogen is human placental insulin receptor.
The insulin receptor is functionally important for negative cooperativity, down-regulation, and beta-subunit tyrosine kinase activity. There are two recognized epitopes of the alpha-subunit. One epitope is close to the insulin-binding site and plays a role in insulin-induced negative cooperativity and down-regulation. The other site (recognized by the monoclonal MA-20 antibody) is at a distance from the insulin-binding site, where it only plays a role in down-regulation. Both epitopes appear to be independent of insulin receptor tyrosine kinase activity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
MA1-10865 was used in immunoprecipitation to investigate the effectiveness of a humanized monoclonal insulin-like growth factor I receptor antibody against human tumor growth
|Burtrum D,Zhu Z,Lu D,Anderson DM,Prewett M,Pereira DS,Bassi R,Abdullah R,Hooper AT,Koo H,Jimenez X,Johnson D,Apblett R,Kussie P,Bohlen P,Witte L,Hicklin DJ,Ludwig DL||Cancer research (63:8912)||2003|
CD220; HHF5; IR
CD220; HHF5; INSR